20 articles
275-patient study tests novel liver-targeted therapy for NASH, a serious form of fatty liver disease affecting millions worldwide.
Natural polyketide from marine bacteria enhances cholesterol removal and improves fat metabolism in liver cells and mice.
New study reveals how the diabetes drug dapagliflozin dramatically alters fat metabolism and kidney function through previously unknown pathways.
A landmark RCT shows finerenone reduces eGFR decline and kidney-cardiovascular events in CKD patients without diabetes.
176-person trial tested whether pioglitazone could improve liver health by targeting insulin resistance in patients with fatty liver disease.
Inclisiran safely reduced LDL cholesterol by 28% in adolescents with familial hypercholesterolemia, offering hope for early intervention.
Scientists discover how FGF21 fights liver disease through a key protein, opening new treatment paths for metabolic dysfunction.
Experimental diabetes drug IC7Fc reduces cholesterol and artery plaque buildup, offering cardiovascular benefits even without weight loss.
A systematic review of 8 studies finds tirzepatide significantly reduces hsCRP and IL-6 across all doses and populations.
New research shows melatonin supplementation during IVF can prevent obesity and glucose problems in offspring by restoring liver function.
50 nm polystyrene nanoplastics accumulate in mouse testes, degrading sperm quality and triggering iron-dependent cell death through a newly identified mitochondrial pathway.
Czech study reveals how strategic fasting and ketogenic diets can reprogram harmful fat production in obesity.
Breakthrough study reveals sepiapterin dramatically outperforms existing PKU therapy, offering hope for better metabolic control.
Major trial tests whether diabetes drug metformin can prevent frailty syndrome that affects millions of aging adults.
Eli Lilly's phase 3 trial pits a novel weekly basal insulin against the gold-standard daily insulin degludec in type 1 diabetes patients.
Enanta Pharmaceuticals tests its FXR agonist EDP-305 in a completed Phase 2 randomized trial for non-alcoholic steatohepatitis.
New research examines whether the cholesterol-lowering drug inclisiran could benefit pediatric patients with genetic high cholesterol.
New research shows phosphatidylserine supplementation reduces liver fat and inflammation while improving glucose control through enhanced fat metabolism.
Novel obesity drug targeting two pathways simultaneously shows unprecedented weight loss results in recent clinical studies.
Turkish researchers tested whether adding high-fat, low-carb eating to intermittent fasting beats traditional IF for obesity treatment.
